Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:50:56.685Z.
Calculation as of: 2026-10-06T12:50:56.685Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e126544d6b89d716845e46a575ce394628d8118dbd26b88e4cb46db2a476fd9c
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Codexis, Inc. (CDXS) | $149.51M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $146.66M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 6.75 | 6.25 | 6.25 | 6.25 |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 65.68 | 52.50 | 80.75 |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.39
Forward EPS (Est.)
$-0.38
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
